SEC Form 4 · accession 0001144204-15-006847
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Beth Taylor
Officer — Corporate Controller
Period of report
Feb 4, 2015
Accepted (ET)
Feb 6, 2015 · 8:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 4, 2015 | A | 4,500 | $0.00 | A | 12,152 | D | |
| Common StockF3 | Feb 6, 2015 | F | 525 | $5.14 | D | 11,627 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $5.10 | Feb 4, 2015 | A | 9,000 | A | — | Feb 4, 2025 | Common Stock | 9,000 | 9,000 | D |
Explanation of responses
- F1Represents restricted stock units that will vest and be paid 1/3 annually over a period of 3 years beginning on February 4, 2016, in the form of one share of common stock for each restricted stock unit.
- F2Includes 505 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on June 15, 2014.
- F3Represents shares withheld to satisfy tax withholding obligations associated with the settlement of 1,356 restricted stock units in the form of Company common stock on a one-for-one basis on February 6, 2015.
- F4Shares subject to the option vest 1/3 annually over a period of 3 years beginning on February 4, 2016.